Flashback Foreword: Gefitinib in Non–Small-Cell Lung Cancer: The IDEAL 1 Trial
Authors: Thomas E. Stinchcombe
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. January 12, 2022 JCO Flashback: Assessing the Effectivity of Gefitinib in Treating Advanced NSCLC (2003). February 15, 2023 Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. January 17, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02660 Journal of Clinical Oncology - published online before print February 15, 2023 PMID: 36791472 Flashback Foreword: Gefitinib in Non–Small-Cell Lung Cancer: The IDEAL 1 Trial Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Division of Medical Oncology, Duke Cancer Institute, Durham, NC2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02660 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2003, Fukuoka et al1 demonstrated the activity of gefitinib, an epidermal growth factor tyrosine kinase inhibitor, in patients with metastatic non–small-cell lung cancer with disease progression after one or two lines of therapy in a phase II trial. The results of this trial contributed to further development of gefitinib in clinically and molecularly selected patient populations.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Gefitinib in Non–Small‐Cell Lung Cancer: The IDEAL 1 TrialThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer JCO Flashback: Assessing the Effectivity of Gefitinib in Treating Advanced NSCLC (2003) Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684